Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

Similar articles for PubMed (Select 22138579)

1.

Adenosine A(2A) receptor ligation inhibits osteoclast formation.

Mediero A, Kara FM, Wilder T, Cronstein BN.

Am J Pathol. 2012 Feb;180(2):775-86. doi: 10.1016/j.ajpath.2011.10.017. Epub 2011 Nov 30.

2.

Activation of adenosine A(2A) receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFκB nuclear translocation.

Mediero A, Perez-Aso M, Cronstein BN.

Br J Pharmacol. 2013 Jul;169(6):1372-88. doi: 10.1111/bph.12227.

3.

Adenosine A2A receptor activation prevents wear particle-induced osteolysis.

Mediero A, Frenkel SR, Wilder T, He W, Mazumder A, Cronstein BN.

Sci Transl Med. 2012 May 23;4(135):135ra65. doi: 10.1126/scitranslmed.3003393.

4.

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.

J Cell Physiol. 2009 Dec;221(3):618-28. doi: 10.1002/jcp.21892.

PMID:
19653230
5.

Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.

Michael H, Härkönen PL, Väänänen HK, Hentunen TA.

J Bone Miner Res. 2005 Dec;20(12):2224-32. Epub 2005 Aug 1.

PMID:
16294275
6.

IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells.

Kitami S, Tanaka H, Kawato T, Tanabe N, Katono-Tani T, Zhang F, Suzuki N, Yonehara Y, Maeno M.

Biochimie. 2010 Apr;92(4):398-404. doi: 10.1016/j.biochi.2009.12.011. Epub 2010 Jan 4.

PMID:
20045440
7.

Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism.

Remen KM, Henning P, Lerner UH, Gustafsson JÅ, Andersson G.

J Biol Chem. 2011 Sep 23;286(38):33084-94. doi: 10.1074/jbc.M111.235937. Epub 2011 Jul 22.

8.

Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T.

J Exp Med. 2000 Jan 17;191(2):275-86.

9.

Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells.

Schulze J, Bickert T, Beil FT, Zaiss MM, Albers J, Wintges K, Streichert T, Klaetschke K, Keller J, Hissnauer TN, Spiro AS, Gessner A, Schett G, Amling M, McKenzie AN, Horst AK, Schinke T.

J Bone Miner Res. 2011 Apr;26(4):704-17. doi: 10.1002/jbmr.269.

PMID:
20939024
10.

Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.

Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, Higashio K, Quinn JM, Gillespie MT, Martin TJ, Suda T, Takahashi N.

Endocrinology. 2001 Aug;142(8):3656-62.

PMID:
11459815
11.

Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro.

Wang L, Zhao R, Shi X, Wei T, Halloran BP, Clark DJ, Jacobs CR, Kingery WS.

Bone. 2009 Aug;45(2):309-20. doi: 10.1016/j.bone.2009.04.203. Epub 2009 Apr 18.

12.

Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist.

He W, Wilder T, Cronstein BN.

Br J Pharmacol. 2013 Nov;170(6):1167-76. doi: 10.1111/bph.12342.

13.

Targeted disruption of ephrin B1 in cells of myeloid lineage increases osteoclast differentiation and bone resorption in mice.

Cheng S, Zhao SL, Nelson B, Kesavan C, Qin X, Wergedal J, Mohan S, Xing W.

PLoS One. 2012;7(3):e32887. doi: 10.1371/journal.pone.0032887. Epub 2012 Mar 5.

15.

Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.

Tsurukai T, Udagawa N, Matsuzaki K, Takahashi N, Suda T.

J Bone Miner Metab. 2000;18(4):177-84.

PMID:
10874596
17.

NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.

Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF.

J Bone Miner Res. 2002 Jul;17(7):1200-10.

PMID:
12096833
18.
19.

Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption.

Wang L, Shi X, Zhao R, Halloran BP, Clark DJ, Jacobs CR, Kingery WS.

Bone. 2010 May;46(5):1369-79. doi: 10.1016/j.bone.2009.11.029. Epub 2009 Dec 2.

20.

Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.

Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M.

Life Sci. 2007 Mar 13;80(14):1311-8. Epub 2007 Jan 23.

PMID:
17306833
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk